Troglitazone data

A pilot trial has shown that the insulin-enhancer troglitazone, now in Phase III trials, lowers glucose levels while allowing patients to decrease or eliminate insulin injections.

In an open-label study, all 17 patients with Type II diabetes were able to decrease daily insulin by 65 percent on average after 12 weeks on the new agent. ...